title: Trick and treat: Ambushing recurrent tumors before they get out of the door.
abstract: Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.
authors.affiliation: Department of Molecular Medicine; Mayo Clinic; Rochester, MN USA.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Boisgerault
authors.affiliation: Department of Molecular Medicine; Mayo Clinic; Rochester, MN USA.
authors.forename: Richard G
authors.initials: RG
authors.lastname: Vile
keywords: VEGF; innate immune response; minimum residual disease; tumor dormancy; tumor recurrence